Rhythm Pharmaceuticals, Inc. (RYTM) stock
RYTMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 5/30265% above fair value
$115.02+5.16 (+4.70%)
Close on Nov 13, 2026Market cap $7.92BP/E –Yield –
Rhythm Pharmaceuticals total assets
Total assets on the balance sheet at the end of each period.
Rhythm Pharmaceuticals's total assets was $437.27M at Jun 30, 2026. For fiscal 2025 it was $480.20M, up 22.4% from the year before. The highest annual figure on record is $480.20M in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $480.20M | +22.4% |
| FY2024 | Dec 31, 2024 | $392.27M | +17.9% |
| FY2023 | Dec 31, 2023 | $332.75M | -13.0% |
| FY2022 | Dec 31, 2022 | $382.48M | +16.1% |
| FY2021 | Dec 31, 2021 | $329.52M | +76.1% |
| FY2020 | Dec 31, 2020 | $187.07M | -39.4% |
| FY2019 | Dec 31, 2019 | $308.52M | +18.6% |
| FY2018 | Dec 31, 2018 | $260.21M | +71.5% |
| FY2017 | Dec 31, 2017 | $151.74M | +1129.7% |
| FY2016 | Dec 31, 2016 | $12.34M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $437.27M | +17.3% |
| Q1 FY2026 | Mar 31, 2026 | $442.32M | +14.4% |
| Q4 FY2025 | Dec 31, 2025 | $480.20M | +22.4% |
| Q3 FY2025 | Sep 30, 2025 | $506.87M | +39.4% |
| Q2 FY2025 | Jun 30, 2025 | $372.73M | -2.4% |
| Q1 FY2025 | Mar 31, 2025 | $386.69M | +49.5% |
| Q4 FY2024 | Dec 31, 2024 | $392.27M | +17.9% |
| Q3 FY2024 | Sep 30, 2024 | $363.57M | +2.6% |
| Q2 FY2024 | Jun 30, 2024 | $381.85M | +23.2% |
| Q1 FY2024 | Mar 31, 2024 | $258.65M | -25.2% |
| Q4 FY2023 | Dec 31, 2023 | $332.75M | -13.0% |
| Q3 FY2023 | Sep 30, 2023 | $354.20M | -9.1% |
| Q2 FY2023 | Jun 30, 2023 | $309.94M | +11.6% |
| Q1 FY2023 | Mar 31, 2023 | $345.68M | +21.4% |
| Q4 FY2022 | Dec 31, 2022 | $382.48M | +16.1% |
| Q3 FY2022 | Sep 30, 2022 | $389.61M | +9.5% |
| Q2 FY2022 | Jun 30, 2022 | $277.68M | -28.5% |
| Q1 FY2022 | Mar 31, 2022 | $284.82M | -32.5% |
| Q4 FY2021 | Dec 31, 2021 | $329.52M | +76.1% |
| Q3 FY2021 | Sep 30, 2021 | $355.82M | +65.1% |
| Q2 FY2021 | Jun 30, 2021 | $388.39M | +59.5% |
| Q1 FY2021 | Mar 31, 2021 | $422.21M | +54.2% |
| Q4 FY2020 | Dec 31, 2020 | $187.07M | -39.4% |
| Q3 FY2020 | Sep 30, 2020 | $215.48M | +21.4% |
| Q2 FY2020 | Jun 30, 2020 | $243.49M | +15.5% |
| Q1 FY2020 | Mar 31, 2020 | $273.76M | +15.8% |
| Q4 FY2019 | Dec 31, 2019 | $308.52M | +18.6% |
| Q3 FY2019 | Sep 30, 2019 | $177.53M | -36.1% |
| Q2 FY2019 | Jun 30, 2019 | $210.89M | -27.7% |
| Q1 FY2019 | Mar 31, 2019 | $236.50M | +69.6% |
| Q4 FY2018 | Dec 31, 2018 | $260.21M | +71.5% |
| Q3 FY2018 | Sep 30, 2018 | $277.73M | +698.0% |
| Q2 FY2018 | Jun 30, 2018 | $291.75M | +2264.4% |
| Q1 FY2018 | Mar 31, 2018 | $139.44M | – |
| Q4 FY2017 | Dec 31, 2017 | $151.74M | – |
| Q3 FY2017 | Sep 30, 2017 | $34.80M | – |
| Q4 FY2016 | Dec 31, 2016 | $12.34M | – |
See a number that looks wrong?